



اللجنة السعودية للرقابة على المنشطات
Saudi Arabian Anti-Doping Committee

رؤية
VISION
2030
المملكة العربية السعودية
KINGDOM OF SAUDI ARABIA

THE PROHIBITED LIST

2021



WORLD
ANTI-DOPING
AGENCY



Edited by:

Mr. Mohammad Nabeel Dobain

Translator

Supervised by:

Mr. Abdulaziz Abdulrahman Almasaed

Executive Director
Saudi Arabian Anti-Doping Committee

Designed by : Omar Ghanem



THE WORLD ANTI-DOPING CODE
INTERNATIONAL
STANDARD

PROHIBITED LIST

2021



This List shall come into effect on 1 January 2021.

The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French.
In the event of any conflict between the English and French versions, the English version shall prevail.



TABLE OF CONTENTS

PREFACE	3
WORLD ANTI-DOPING AGENCY "WADA"	4
SAUDI ARABIAN ANTI-DOPING COMMITTEE "SAADC"	4
WADA CODE	4
"PROHIBITED LIST" INTERNATIONAL STANDARD	5
HOW IS THE LIST UPDATING?	5
THE SAUDI ANTI-DOPING PROGRAM	5
ANTI-DOPING RULE VIOLATIONS	7
THERAPEUTIC USE EXEMPTION "TUE"	8

Please note that the list of examples of medical conditions below is not inclusive.

SUBSTANCES & METHODS PROHIBITED AT ALL TIMES

S0 Non-approved substances	11
S1 Anabolic agents Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. male hypogonadism.	11
S2 Peptide hormones, growth factors, related substances, and mimetics Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaemia, male hypogonadism, growth hormone deficiency.	13
S3 Beta-2 agonists Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. asthma and other respiratory disorders.	15
S4 Hormone and metabolic modulators Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. breast cancer, diabetes, infertility (female), polycystic ovarian syndrome.	16
S5 Diuretics and masking agents Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension.	17
M1 – M2 – M3 Prohibited Methods Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaphylaxis, attention deficit hyperactivity disorders (ADHD), cold and influenza symptoms.	18

SUBSTANCES & METHODS PROHIBITED IN-COMPETITION

S6 Stimulants Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. pain, including from musculoskeletal injuries.	19
S7 Narcotics Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. allergy, anaphylaxis, asthma, inflammatory bowel disease.	21
S8 Cannabinoids	22
S9 Glucocorticoids Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension.	22

SUBSTANCES PROHIBITED IN PARTICULAR SPORTS

P1 Beta-blockers	23
2021 Monitoring Program	24
Summary of Major Modifications and Explanatory Notes	25

PREFACE

The Saudi Arabian Anti-Doping Committee (SAADC), by preparing and publishing this booklet, helps providing athletes and Athlete's Support Personnel, with the required and important information about the prohibited substances and methods in sport. This kind of activity also falls within the program of awareness which represents one of the main pillars of the Saudi Anti-Doping program.

The list of prohibited substances and methods is one of the international standards emanating from the World Anti-Doping Agency (WADA).

It is very important for all the staff of the sport community to know some facts about the List in order to get the maximum benefits. Such facts can be summarized as follows:

- 1- The list shall come into effect on 01/01/2021 until 31/12/2021.
- 2- All athletes and Athletes' Support Personnel must refer to this list prior to using or prescribing any medications.
- 3- Names mentioned in the List refer to the scientific and chemical properties of pharmaceutical compounds which are different from the brand-names of medications in pharmacies, and stores selling medicine, dietary and food supplements.
- 4- The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail.
- 5- The issuance of the 2021 WADA Prohibited List in Arabic by the Saudi Arabian Anti-Doping Committee shall enable the 2021 Prohibited List to be shared across countries in the region.
- 6- The World Anti-Doping Agency wishes to thank and appreciate the Saudi Arabian Anti-Doping Committee for its valuable contribution to the development of the Arabic version of the 2021 WADA Prohibited List. This shall enable the 2021 Prohibited List to be shared across countries in the region, so that the WADA, the Public Authorities, and the Sport Movement can work together to protect clean athletes, and true play.

Our best wishes to all sport teams and clubs with success and for their contribution to keeping sport as a field of fair competition and maintaining the health of all athletes.

● World Anti-Doping Agency "WADA"

The World Anti-Doping Agency is an independent international organization responsible for promoting, coordinating and monitoring the fight against doping in sport in all its aspects, pursuing doping-free sport. It was established in 1999, based in Canada.

● Saudi Arabian Anti-Doping Committee "SAADC"

SAADC is a consultative, legislative and executive committee, attached to the Board of Directors of the Saudi Arabian National Olympic Committee. It is an independent distinct body with its own legal personality, in all anti-doping matters in the Kingdom of Saudi Arabia. It is the sole authority to represent Saudi Arabia at international anti-doping events. SAADC operates within the policies of Saudi Arabian National Olympic Committee under the supervision of the Ministry of Sport in Saudi Arabia. It was established in 2004.

● WADA CODE

The World Anti-Doping Code (Code) is the core document that harmonizes anti-doping policies, rules and regulations within sport organizations and among public authorities around the world. It works in conjunction with other seven International Standards which aim to foster consistency among anti-doping organizations in various areas: Prohibited List, Testing and Investigation, Laboratories, Therapeutic Use Exemptions (TUEs), Protection of Privacy and Personal Information, and Code Compliance by Signatories, Results Management and Education.

To date, more than 700 sport organizations have accepted the World Anti-Doping Code. Code acceptance means that a sport organization agrees to the principles of the Code and agrees to implement and comply with the Code. The implementation of the Code is the process that an anti-doping organization goes through to amend its rules and policies so that all mandatory articles and principles of the Code are included. WADA monitors implementation of and compliance with the Code.



● "Prohibited List" International Standard

List of prohibited substances and methods (the Prohibited List) is one of the eight international standards that determines what are the materials and methods prohibited in both IN and OUT of competition. It also refers to the list of prohibited substances in particular sports. The prohibited substances and methods on the List are classified by different classes (e.g., steroids, stimulants, gene doping). The list is updated annually.

● How is the list updating?

The List is developed through a consultative and intensive process where it starts by circulating and sending a draft to more than 1,700 persons who are related in particular to the anti-doping and substances matters to get their comments and notes . All received comments are processed by the List Expert Group and Health, Medical and Research Committee, of the World Anti-Doping Agency that is composed of international anti-doping scientists and experts. The List Committee analyzes all these comments and consultations and reports last findings to the on WADA Medical and Research Committee, which in turn sends its final recommendations to the Executive Committee, to confirm the final draft in their annual meeting which is held in September every year. (Executive Committee , is the final decision-making body to approve all policies related to international standards).

● The Saudi Anti-Doping Program:

The Saudi Anti-doping program seeks to preserve what is intrinsically valuable about sport. This intrinsic value is often referred to as "the spirit of sport"; it is the essence of Olympism; it is how we play true. The spirit of sport is the celebration of the human spirit, body and mind, and is characterized by the following values:

- Ethics, fair play and honesty
- Health
- Excellence in performance
- Character and education
- Fun and joy
- Teamwork
- Dedication and commitment
- Respect for rules and laws
- Respect for self and other Participants
- Courage
- Community and solidarity

Doping is fundamentally contrary to the spirit of sport.

The Saudi Arabian National anti-doping Program is conducted according to the following main items:

- Education, Training and Research.
- Therapeutic Use Exemption.
- Testing.
- Result Management.
- Sanctions.
- Appeals.

Scope

These Anti-Doping Rules shall apply to the following:

- Saudi Arabian Olympics Committee
- Saudi Arabian Anti-Doping Committee (SAADC)
- Saudi Arabian Sports Federations and Organizations
- All participants in programs and activities supervised by Saudi Sports Federations and Organizations.

Any Person who is not a member of a Saudi Arabian National Federation and who fulfills the requirements to be part of SAADC Registered Testing Pool, must become a member of the Person's National Federation, and shall make himself or herself available for Testing, at least twelve months before participating in International Events or Events of his or her National Federation.

Athletes and Athlete Support Personnel are also bound by SAADC anti-doping rules. Each Saudi Sports Federation shall take the necessary steps to ensure that all Athletes and Athlete Support Personnel within its authority and all affiliated associations are informed and bound by these rules.

These Anti-Doping Rules shall apply to all Doping Controls over which SAADC has jurisdiction.

ANTI-DOPING RULE VIOLATIONS

Doping is defined as the occurrence of one or more of the anti-doping rule violations shown below (athlete and other persons should be responsible for knowing what constitutes a violation of anti-doping rules, and the prohibited substances and methods):

1. Presence of a Prohibited Substance or its Metabolites or Markers in an Athlete's sample.
2. Use or Attempted Use by an Athlete of a Prohibited Substance or a Prohibited Method.
3. Evading, refusing or failing to submit to Sample collection after notification as authorized in the Saudi Arabian Anti-Doping Rules.
4. Whereabouts Failures by an Athlete
5. Tampering or Attempted Tampering with any part of Doping Control by an Athlete or Other Person
6. Possession of a Prohibited Substance or a Prohibited Method by an Athlete or Athlete Support Person
7. Trafficking or Attempted Trafficking in any Prohibited Substance or Prohibited Method by an Athlete or Other Person
8. Administration or Attempted Administration by an Athlete or Other Person to any Athlete In-Competition of any Prohibited Substance or Prohibited Method, or Administration or Attempted Administration to any Athlete Out-of-Competition of any Prohibited Substance or any Prohibited Method that is Prohibited Out-of-Competition
9. Complicity or Attempted Complicity by an Athlete or Other Person
10. Prohibited Association by an Athlete or Other Person
11. Acts by an Athlete or Other Person to Discourage or Retaliate Against Reporting to Authorities

Every Athlete are responsible to ensure non-entry of any banned substance into his body.

Therapeutic Use exemption "TUE":

Many athletes suffer from medical issues, taking different types of drugs they need. Such drugs may contain prohibited substances which, upon using prior or during the In and Out-of-competition, may lead to one of the anti-doping violations. For this purpose, a Therapeutic Use Exemption Committee "TUEC" had been established. It is a Sub-Committee of the Saudi Arabian Anti-Doping Committee, the role of which is to review applications from athletes in various sports and to allow or deny the athlete's use of such therapeutic material In and Out-of-Competitions.

Goal of TUE committee is: to reach dope-free sport community allowing equal opportunities for everyone in various sports competitions.

Applications should be submitted to:

The Therapeutic Use Exemption Committee "**TUEC**" after filling up the required forms, along with an explanation of the pathological condition, indications and justifications for the request of the exemption.

Forms are available on the SAADC Committee's website:

WWW.SAADC.COM

Should be submitted either:

- 1 - By hand to SAADC's headquarters –3rd Floor, Prince Faisal bin Fahd Olympic Complex - Riyadh, or
- 2 - Email to: **tuec@saadc.org**, or
- 3 - Fax to: 011-4831279

THE 2021 PROHIBITED LIST

WORLD ANTI-DOPING CODE

VALID 1 JANUARY 2021



Introduction

The Prohibited List is a mandatory International Standard as part of the World Anti-Doping Program.

The List is updated annually following an extensive consultation process facilitated by WADA. The effective date of the List is 01 January 2021.

The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail.

Below are some terms used in this List of Prohibited Substances and Prohibited Methods.

Prohibited In-Competition

Subject to a different period having been approved by WADA for a given sport, the In-Competition period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a Competition in which the Athlete is scheduled to participate until the end of the Competition and the Sample collection process.

Prohibited at all times

This means that the substance or method is prohibited In- and Out-of-Competition as defined in the Code.

Specified and non-Specified

As per Article 4.2.2 of the World Anti-Doping Code, “for purposes of the application of Article 10, all Prohibited Substances shall be Specified



Substances except as identified on the Prohibited List. No Prohibited Method shall be a Specified Method unless it is specifically identified as a Specified Method on the Prohibited List". As per the comment to the article, "the Specified Substances and Methods identified in Article 4.2.2 should not in any way be considered less important or less dangerous than other doping substances or methods. Rather, they are simply substances and methods which are more likely to have been consumed or used by an Athlete for a purpose other than the enhancement of sport performance."

Substances of Abuse

Pursuant to Article 4.2.3 of the Code, Substances of Abuse are substances that are identified as such because they are frequently abused in society outside of the context of sport. The following are designated Substances of Abuse: cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/"ecstasy"), tetrahydrocannabinol (THC).

Published by:
World Anti-Doping Agency
URL: www.wada-ama.org
Tel: +1 514 904 9232
Fax: +1 514 904 8650
E-mail: code@wada-ama.org



S0 NON-APPROVED SUBSTANCES

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are Specified Substances.

Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

S1 ANABOLIC AGENTS

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are non-Specified Substances.

Anabolic agents are prohibited.

1. ANABOLIC ANDROGENIC STEROIDS (AAS)

When administered exogenously, including but not limited to:

- 1-Androstenediol (5 α -androst-1-ene-3 β ,17 β -diol)
- 1-Androstenedione (5 α -androst-1-ene-3,17-dione)
- 1-Androsterone (3 α -hydroxy-5 α -androst-1-ene-17-one)
- 1-Epiandrosterone (3 β -hydroxy-5 α -androst-1-ene-17-one)
- 1-Testosterone (17 β -hydroxy-5 α -androst-1-en-3-one)
- 4-Androstenediol (androst-4-ene-3 β ,17 β -diol)
- 4-Hydroxytestosterone(4,17 β -dihydroxyandrost-4-en-3-one)
- 5-Androstenedione (androst-5-ene-3,17-dione)
- 7 α -hydroxy-DHEA
- 7 β -hydroxy-DHEA
- 7-Keto-DHEA
- 19-Norandrostenediol (estr-4-ene-3,17-diol)
- 19-Norandrostenedione (estr-4-ene-3,17-dione)
- Androstanolone (5 α -dihydrotestosterone,17 β -hydroxy-5 α -androstan-3-one)
- Androstenediol (androst-5-ene-3 β ,17 β -diol)
- Androstenedione (androst-4-ene-3,17-dione)
- Bolasterone

- Boldenone
- Boldione (androsta-1,4-diene-3,17-dione)
- Calusterone
- Clostebol
- Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17 α -ol)
- Dehydrochlormethyltestosterone (4-chloro-17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one)
- Desoxymethyltestosterone (17 α -methyl-5 α -androst-2-en-17 β -ol and 17 α -methyl-5 α -androst-3-en-17 β -ol)
- Drostanolone
- Epiandrosterone (3 β -hydroxy-5 α -androstan-17-one)
- Epi-dihydrotestosterone (17 β -hydroxy-5 β -androstan-3-one)
- Epi-testosterone
- Ethylestrenol (19-norpregna-4-en-17 α -ol)
- Fluoxymesterone
- Formebolone
- Furazabol (17 α -methyl [1,2,5]oxadiazolo[3',4':2,3]-5 α -androstan-17 β -ol)
- Gestrinone
- Mestanolone
- Mesterolone
- Metandienone (17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one)
- Metenolone
- Methandriol
- Methasterone (17 β -hydroxy-2 α ,17 α -dimethyl-5 α -androstan-3-one)
- Methyl-1-testosterone (17 β -hydroxy-17 α -methyl-5 α -androst-1-en-3-one)
- Methylclostebol
- Methyldienolone (17 β -hydroxy-17 α -methylestra-4,9-dien-3-one)
- Methylnortestosterone (17 β -hydroxy-17 α -methylestr-4-en-3-one)
- Methyltestosterone
- Methyltrienolone (methyltrienolone, 17 β -hydroxy-17 α -methylestra-4,9,11-trien-3-one)
- Mibolerone
- Nandrolone (19-nortestosterone)
- Norboletone
- Norclostebol (4-chloro-17 β -ol-estr-4-en-3-one)
- Norethandrolone
- Oxabolone
- Oxandrolone
- Oxymesterone
- Oxymetholone
- Prasterone (dehydroepiandrosterone, DHEA, 3 β -hydroxyandrost-5-en-17-one)

- Prostanazol (17 β -[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5 α -androstane)
 - Quinbolone
 - Stanozolol
 - Stenbolone
 - Testosterone
 - Tetrahydrogestrinone (17-hydroxy-18ahomo-19-nor-17a-pregna-4,9,11-trien-3-one)
 - Trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one)
- and other substances with similar chemical structure or similar biological effect(s).

2. OTHER ANABOLIC AGENTS

Including, but not limited to:

- Clenbuterol;
- Selective androgen receptor modulators (SARMs, e.g. andarine, LGD-4033 (ligandrol), enobosarm (ostarine) and RAD140);
- Tibolone;
- Zeranol;
- Zilpaterol.

S2 PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES AND MIMETICS

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are non-Specified Substances.

The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:

1. ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS

Including, but not limited to:

- 1.1 Erythropoietin-Receptor Agonists, e.g.
 - Darbepoietins (dEPO);
 - Erythropoietins (EPO);
 - EPO-based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)];
 - EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide).

- 1.2 Hypoxia-inducible factor (HIF) activating agents, e.g.
Cobalt;
Daprodustat (GSK1278863);
IOX2;
Molidustat (BAY 85-3934);
Roxadustat (FG-4592);
Vadadustat (AKB-6548);
Xenon.
- 1.3 GATA inhibitors, e.g.
K-11706.
- 1.4 Transforming growth factor beta (TGF- β) signalling inhibitors, e.g.
Luspatercept;
Sotatercept.
- 1.5 Innate repair receptor agonists, e.g.
Asialo EPO;
Carbamylated EPO (CEPO).


2. PEPTIDE HORMONES AND THEIR RELEASING FACTORS

- 2.1 Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors in males, e.g. buserelin, deslorelin, gonadorelin, goserelin, leuprorelin, nafarelin and triptorelin;
- 2.2 Corticotrophins and their releasing factors, e.g. corticorelin;
- 2.3 Growth Hormone (GH), its fragments and releasing factors, including, but not limited to:
Growth Hormone fragments, e.g. AOD-9604 and hGH 176-191;
Growth hormone-releasing hormone (GHRH) and its analogues, e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin;
Growth hormone secretagogues (GHS), e.g. lenomorelin (ghrelin) and its mimetics, e.g. anamorelin, ipamorelin, macimorelin and tabimorelin;
GH-releasing peptides (GHRPs), e.g. alexamorelin, GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and examorelin (hexarelin).

3. GROWTH FACTORS AND GROWTH FACTOR MODULATORS

Including, but not limited to:

- Fibroblast Growth Factors (FGFs);
- Hepatocyte Growth Factor (HGF);
- Insulin-like Growth Factor-1 (IGF-1) and its analogues;



- Mechano Growth Factors (MGFs);
- Platelet-Derived Growth Factor (PDGF);
- Thymosin- β 4 and its derivatives e.g. TB-500;
- Vascular-Endothelial Growth Factor (VEGF);

and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.

S3 BETA-2 AGONISTS

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are Specified Substances.

All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited, including, but not limited to:

- Arformoterol
- Fenoterol
- Formoterol
- Higenamine
- Indacaterol
- Levosalbutamol
- Olodaterol
- Procaterol
- Reproterol
- Salbutamol
- Salmeterol
- Terbutaline
- Tretioquinol trimetoquinol)
- Tulobuterol
- Vilanterol

EXCEPTIONS

- Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 800 micrograms over 12 hours starting from any dose;
- Inhaled formoterol: maximum delivered dose 54 micrograms over 24 hours;
- Inhaled salmeterol: maximum 200 micrograms over 24 hours.
- Inhaled vilanterol: maximum 25 micrograms over 24 hours.

NOTE

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above..

S4 HORMONE AND METABOLIC MODULATORS

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

Prohibited substances in classes S4.1 and S4.2 are Specified Substances. Those in classes S4.3 and S4.4 are non-Specified Substances.

The following hormone and metabolic modulators are prohibited:

1. Aromatase inhibitors

Including, but not limited to:

- 2-Androstenol (5 α -androst-2-en-17-ol);
- 2-Androstenone (5 α -androst-2-en-17-ol);
- 3-Androstenol (5 α -androst-3-en-17-ol)
- 3-Androstenone (5 α -androst-3-en-17-one)
- 4-Androstene-3,6,17 trione (6-oxo)
- Aminoglutethimide
- Anastrozole
- Androsta-1,4,6-triene-3,17-dione (androstatrienedione)
- Androsta-3,5-diene-7,17-dione (arimistane)
- Exemestane
 - Formestane
- Letrozole
 - Testolactone

2. ANTI-ESTROGENIC SUBSTANCES [ANTI-ESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)]

Including, but limited to:

- Bazedoxifene
- Fulvestrant
- Tamoxifen
- Clomifene
- Ospemifene
- Toremifene
- Cyclofenil
- Raloxifene

3. Agents preventing activin receptor IIB activation

Including, but not limited, to:

- Activin A-neutralizing antibodies;
- Activin receptor IIB competitors such as:
 - Decoy activin receptors (e.g. ACE-031)
- Anti-activin receptor IIB antibodies (e.g. bimagrumab)
- Myostatin inhibitors such as:
 - Agents reducing or ablating myostatin expression
 - Myostatin-binding proteins (e.g. follistatin, myostatin propeptide)
 - Myostatin-neutralizing antibodies (e.g. domagrozumab, landogrozumab, stamulumab).

4. Metabolic modulators:

- 4.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, SR9009; and peroxisome proliferator- activated receptor delta (PPAR δ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516);
- 4.2 Insulins and insulin-mimetics;
- 4.3 Meldonium;
- 4.4 Trimetazidine

S5 DIURETICS AND MASKING AGENTS

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All Prohibited substances in this class are Specified Substances.

The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s). Including, but not limited to:

- Desmopressin; probenecid; plasma expanders, e.g. intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol.
- Acetazolamide; amiloride; bumetanide; canrenone; chlortalidonone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflu-methiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan.

EXCEPTIONS

- Drospirenone; pamabrom; and topical ophthalmic administration of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide);
- Local administration of felypressin in dental anesthesia.

NOTE

The detection in an Athlete's Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent.

PROHIBITED METHODS

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited methods in this class are non-Specified except methods in M2.2. which are Specified Methods.

M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS

The following are prohibited:

- 1- The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system.
- 2- Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to:
Perfluorochemicals; efaroxiral (RSR13) and modified haemoglobin products, e.g. Haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation.
- 3- Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

M2. CHEMICAL AND PHYSICAL MANIPULATION

The following are prohibited:

- 1- Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to:
Sample substitution and/or adulteration, e.g. addition of proteases to Sample.
- 2- Intravenous infusions and/or injections of more than a total of 100 mL per 12 hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations.

M3. GENE AND CELL DOPING

The following, with the potential to enhance sport performance, are prohibited:

- 1- The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or alter gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technologies.
- 2- The use of normal or genetically modified cells.

S6 STIMULANTS

PROHIBITED IN-COMPETITION

All prohibited substances in this class are Specified Substances except those in S6.A, which are non-Specified Substances.

Substances of Abuse in this section:

cocaine and methylenedioxymethamphetamine (MDMA /“ecstasy”)

All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited .

Stimulants include:

A: Non-Specified Stimulants:

- Adrafinil;
- Amfepramone;
- Amfetamine;
- Amfetaminil;
- Amiphenazole;
- Benfluorex;
- Benzylpiperazine;
- Bromantan;
- Clobenzorex;
- Cocaine;
- Cropropamide;
- Crotetamide;
- Fencamine;
- Fenetylline;
- Fenfluramine;
- Fenproporex;
- Fonturacetam [4-phenylpiracetam (carphedon)];
- Furfenorex;
- Lisdexamfetamine;
- Mefenorex;
- Mephentermine;
- Mesocarb;
- Metamfetamine(d-);
- p-methylamphetamine;
- Modafinil;
- Norfenfluramine;
- Phendimetrazine;
- Phentermine;
- Prenylamine;
- Prolintane.

A stimulant not expressly listed in this section is a Specified Substance.

B: Specified Stimulants

Including, but not limited to:

- 3-Methylhexan-2-amine (1,2-dimethylpentylamine);
- 4-Methylhexan-2-amine (methylhexaneamine);
- 4-Methylpentan-2-amine (1,3-dimethylbutylamine);
- 5-Methylhexan-2-amine (1,4-dimethylpentylamine);
- Benzfetamine;
- Cathine**;
- Cathinone and its analogues, e.g. mephedrone, methedrone, and α -pyrrolidinovalerophenone;
- Dimetamfetamine (dimethylamphetamine);
- Ephedrine***;
- Epinephrine**** (adrenaline);
- Etamivan;
- Etilamfetamine;
- Etilefrine;
- Famprofazone;
- Fenbutrazate;
- Fencamfamin;
- Heptaminol;
- Hydroxyamfetamine (parahydroxyamphetamine);
- Isometheptene;
- Levmetamfetamine;
- Meclofenoxate;
- Methylenedioxyamphetamine;
- Methylphenidine***;
- Methylphenidate;
- Nikethamide;
- Norfenefrine;
- Octodrine (1,5-dimethylhexylamine);
- Octopamine;
- Oxilofrine (methylsynephrine);
- Pemoline;
- Pentetrazol;
- Phenethylamine and its derivatives;
- Phenmetrazine;
- Phenpromethamine;
- Propylhexedrine;
- Pseudoephedrine*****;
- Selegiline;
- Sibutramine;
- Strychnine;
- Tenamfetamine (methylenedioxyamphetamine);
- Tuaminoheptane;

and other substances with a similar chemical structure or similar biological effect(s).

EXCEPTIONS

- Clonidine
- Imidazole derivatives for dermatological, nasal or ophthalmic use (e.g. brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline, xylometazoline) and those stimulants included in the 2021 Monitoring Program*.
 - * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2021 Monitoring Program, and are not considered Prohibited Substances.
 - ** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter.
 - *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter.
 - **** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents.
 - ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter.

S7 NARCOTICS

PROHIBITED IN-COMPETITION

All prohibited substances in this class are Specified Substances.
Substances of Abuse in this section: diamorphine (heroin)

The following narcotics, including all optical isomers, e.g. d- and l- where relevant, are prohibited:

- Buprenorphine;
- Dextromoramide;
- Diamorphine (heroin);
- Fentanyl and its derivatives;
- Hydromorphone;
- Methadone
- Morphine;
- Nicomorphine
- Oxycodone;
- Oxymorphone;
- Pentazocine;
- Pethidine.

S8 CANNABINOIDS

PROHIBITED IN-COMPETITION

All prohibited substances in this class are Specified Substances.
Substances of Abuse in this section: tetrahydrocannabinol (THC)

All natural and synthetic cannabinoids are prohibited, e.g.

- In cannabis (hashish, marijuana) and cannabis products
- Natural and synthetic tetrahydrocannabinols (THCs)
- synthetic cannabinoids that mimic the effects of THC

EXCEPTIONS

- Cannabidiol

S9 GLUCOCORTICOIDS

PROHIBITED IN-COMPETITION

All prohibited substances in this class are Specified Substances.

All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.

Including but not limited to:

- Beclometasone
- Betamethasone
- Budesonide
- Ciclesonide
- Cortisone
- Deflazacort
- Dexamethasone
- Flucortolone
- Flunisolide
- Fluticasone
- Hydrocortisone
- Methylprednisolone
- Mometasone
- Prednisolone
- Prednisone
- Triamcinolone acetonide

P1 BETA-BLOCKERS

PROHIBITED IN-COMPETITION

All prohibited substances in this class are Specified Substances.

Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated.(*)

• Archery (WA)*
• Automobile (FIA)
• Billiards (all disciplines) (WCBS)
• Darts (WDF)
• Golf (IGF)
• Shooting (ISSF, IPC)*
• Skiing/Snowboarding (FIS) in ski jumping, freestyle aericals/halfpipe and snowboard halfpipe/big air
• Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting, and variable weight apnoea.

*Also prohibited Out-of-Competition

Including, but not limited to:

- Acebutolol
- Alprenolol
- Atenolol
- Betaxolol
- Bisoprolol
- Bunolol
- Carteolol
- Carvedilol
- Celiprolol
- Esmolol
- Labetalol
- Metipranolol
- Metoprolol
- Nadolol
- Nebivolol
- Oxprenolol
- Pindolol
- Propranolol
- Sotalol
- Timolol

www.wada-ama.org

THE 2021 MONITORING PROGRAM*



The following substances are placed on the 2021 Monitoring Program:

1. Anabolic Agents:

In and Out-of-Competition: Ecdysterone

2. Beta-2 Agonists:

In and Out-of-Competition: Salmeterol and vilanterol below the Minimum Reporting Level.

3. 2-ethylsulfanyl-1H-benzimidazole (bemitil):

In and Out-of-Competition

4. Stimulants:


In-Competition only: Bupropion, caffeine, nicotine, phenylephrine, phenylpropranolamine, piperidrol and synephrine.

5. Narcotics:

In-Competition only: Codeine, hydrocodone and tramadol.

6. Glucocorticoids:

In-Competition (by routes of administration other than oral, intravenous, intramuscular, or rectal) and Out-of-Competition (all routes of administration)



SUMMARY OF MAJOR MODIFICATIONS AND EXPLANATORY NOTES



2021 PROHIBITED LIST

Redesign of the List

- The 2021 Prohibited List is redesigned to improve navigation and usability.

Specified Methods

- M2.2 is now a Specified Method in accordance with Article 4.2.2 of the 2021 World Anti-Doping Code (the Code).

Substances of Abuse

- Article 4.2.3 of the Code defines Substances of Abuse as those “Prohibited Substances which are specifically identified as Substances of Abuse on the Prohibited List because they are frequently abused in society outside of the context of sport.”
- Cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/“ecstasy”) and tetrahydrocannabinol (THC) are designated as Substances of Abuse.
- Other substances are currently under review and may be designated as Substances of Abuse in the future.

SUMMARY OF MAJOR MODIFICATIONS AND EXPLANATORY NOTES



SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

PROHIBITED SUBSTANCES

S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics

- Transforming growth factor-beta (TGF- β) signalling inhibitors are now included with their full rather than abbreviated name.
- IOX2 is added as an example of a hypoxia-inducible factor (HIF) activating agent.

S3 Beta- 2 Agonists

- Inhaled vilanterol is now permitted up to the manufacturer's maximum recommended dose. The dose is expressed as the metered dose of 25 micrograms which is equivalent to a delivered dose of 22 micrograms.
- It is clarified that arformoterol and levosalmolamol are prohibited by adding them as examples.

S4 Hormone and Metabolic Modulators

- Sub-classes 4.2 and 4.3 were amalgamated to become anti-estrogenic substances (including selective estrogen receptor modulators (SERMs)). This clarification in terminology reflects that, for anti-doping purposes, all these substances act by a common mechanism of binding to estrogen receptors and blocking estrogen action. This clarification did not add or remove any substances from this category.

S5 Diuretics and Masking Agents

- The wording regarding the exception to allow the ophthalmic use of carbonic anhydrase inhibitors is clarified as "topical ophthalmic administration".

PROHIBITED METHODS

M2. Chemical and Physical Manipulation

- As explained above, M2.2 is changed from a non-Specified to a Specified Method.

SUMMARY OF MAJOR MODIFICATIONS AND EXPLANATORY NOTES



SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION

PROHIBITED SUBSTANCES

S6 Stimulants

- Examples of imidazole derivatives for topical use are added to the exceptions. These are brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline and xylometazoline.

S9 Glucocorticoids

- Additional examples of glucocorticoids are added to the List. The names of some existing examples are clarified to better reflect the active drug compound.
- As proposed in the draft 2021 Prohibited List circulated for consultation to stakeholders in May 2020, WADA's Executive Committee approved, at its 14-15 September 2020 meeting, prohibiting all injectable routes of administration of glucocorticoids during the In-Competition period. Examples of injectable routes of administration include: intravenous, intramuscular, periarticular, intra-articular, peritendinous, intratendinous, epidural, intrathecal, intrabursal, intralesional (e.g. intrakeloid), intradermal, and subcutaneous. However, in order to thoroughly and widely communicate the rule changes and to allow sufficient time for information and education, the Executive Committee decided to introduce the prohibition of all injectable glucocorticoid routes and the implementation of the new rules on 1 January 2022. This one-year period will allow, for example, Athletes and medical personnel to get a better understanding of the practical implementation of the washout periods, Laboratories to update their procedures to incorporate the revised and substance-specific new reporting values, and sports authorities to develop educational tools for Athletes, medical and support personnel, addressing the safe use of glucocorticoids for clinical purposes in anti-doping.

P1 Beta-blockers

- Nebivolol was added as an example.

SUMMARY OF MAJOR MODIFICATIONS AND EXPLANATORY NOTES



MONITORING PROGRAM

Beta-2 Agonists: In and Out-of-Competition:

- Any combination of beta-2 agonists was removed as the required prevalence data were obtained.
 - Findings for salmeterol and vilanterol below the Minimum Reporting Level are included in the Monitoring Program to better monitor their therapeutic use vs risk of abuse.
- * For further information on previous modifications and clarifications, please consult the Prohibited List Q & A at www.wada-ama.org/en/questions-answers/prohibited-list-qa.